{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:18:12Z","timestamp":1784557092132,"version":"3.55.0"},"reference-count":20,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"unspecified","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,6,22]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"\n Objectives<\/jats:title>\n Medication adherence is a key determinant of treatment effectiveness in chronic inflammatory diseases but data in Beh\u00e7et\u2019s syndrome (BS) remain limited. This study evaluated medication adherence in a real-world cohort of patients with BS and explored demographic and clinical factors associated with reduced adherence.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a monocentric cross-sectional study including 125 patients with BS followed at a tertiary referral centre. Adherence was assessed using the validated 8-item Morisky Medication Adherence Scale (MMAS-8). Patients were classified as having high (score=8), intermediate (score 6\u2013<8) or low adherence (score<6). Disease activity was evaluated using the Beh\u00e7et\u2019s Disease Current Activity Form and the Beh\u00e7et\u2019s Disease Activity Index. Associations between adherence and clinical variables were analysed using Spearman correlation and non-parametric tests.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The mean MMAS-8 Score was 6.82\u00b11.32. High adherence was observed in 29.6% of patients, intermediate adherence in 48.8% and low adherence in 21.6%. Lower adherence was more frequent among patients in the lower age quartiles. No significant associations were observed between adherence and sex, disease duration, disease activity indices or treatment class.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Medication adherence in BS appeared generally satisfactory, although a relevant proportion of patients reported suboptimal adherence. These findings confirm, in a BS-specific real-world setting, previously reported associations between age and medication adherence observed in chronic diseases. Routine adherence assessment may help identify patients at higher risk of poor treatment compliance and support personalised management strategies.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/rmdopen-2026-006982","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:50:23Z","timestamp":1784555423000},"page":"e006982","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Medication adherence in Beh\u00e7et\u2019s syndrome: real-world data from a tertiary referral cohort"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-9611","authenticated-orcid":false,"given":"Rosaria","family":"Talarico","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliero-Universitaria Pisana, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Di Cianni","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliero-Universitaria Pisana, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"},{"name":"Department of Medical Biotechnologies, University of Siena, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Sulis","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliero-Universitaria Pisana, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Lubrano Lavadera","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliero-Universitaria Pisana, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5537-6043","authenticated-orcid":false,"given":"Diana","family":"Marinello","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliero-Universitaria Pisana, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5937-4574","authenticated-orcid":false,"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliero-Universitaria Pisana, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"2026072006501783000_12.3.e006982.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02629-6"},{"key":"2026072006501783000_12.3.e006982.2","first-page":"1699","article-title":"Beh\u00e7et\u2019s syndrome: one year in review 2025","volume":"43","author":"Hatemi","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"2026072006501783000_12.3.e006982.3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1605714","article-title":"Assessing disease phenotypes in Beh\u00e7et\u2019s syndrome: insights from a multiple correspondence analysis","volume":"16","author":"Talarico","year":"2025","journal-title":"Front Immunol"},{"key":"2026072006501783000_12.3.e006982.4","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ard.2026.02.009","article-title":"EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome: 2025 update","volume":"85","author":"Hatemi","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"2026072006501783000_12.3.e006982.5","doi-asserted-by":"crossref","unstructured":"Talarico R , Italiano N , Emmi G , et al . Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Beh\u00e7et\u2019s syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial. Ann Rheum Dis 2024. doi:10.1136\/ard-2024-226113","DOI":"10.1136\/ard-2024-226113"},{"key":"2026072006501783000_12.3.e006982.6","unstructured":"World Health Organization . Adherence to long-term therapies: evidence for action. 2003. Available: https:\/\/iris.who.int\/handle\/10665\/42682"},{"key":"2026072006501783000_12.3.e006982.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218986"},{"key":"2026072006501783000_12.3.e006982.8","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1093\/rheumatology\/keaf148","article-title":"Active disease, fibromyalgia and exposure to glucocorticoids differentially associate with sleep and circadian parameters in Beh\u00e7et\u2019s syndrome","volume":"64","author":"Colitta","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026072006501783000_12.3.e006982.9","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.1093\/rheumatology\/keaf326","article-title":"Sleep and circadian parameters in Beh\u00e7et\u2019s syndrome: a comparative analysis using actigraphy and questionnaires","volume":"64","author":"Colitta","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026072006501783000_12.3.e006982.10","first-page":"1810","article-title":"Promoting patients\u2019 empowerment in rheumatic diseases: the perspective of the International Society of Beh\u00e7et\u2019s Disease Working Group on patient empowerment, adherence to therapy and patients\u2019 education","volume":"43","author":"Cianni","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"2026072006501783000_12.3.e006982.11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.55563\/clinexprheumatol\/1lx7a5","article-title":"Adherence to treatment in Beh\u00e7et\u2019s syndrome: a multi-faceted issue","volume":"39 Suppl 132","author":"Pirri","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2026072006501783000_12.3.e006982.12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jbspin.2018.08.006","article-title":"Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: a process based on literature reviews and expert consensus","volume":"86","author":"Gossec","year":"2019","journal-title":"Joint Bone Spine"},{"key":"2026072006501783000_12.3.e006982.13","doi-asserted-by":"crossref","DOI":"10.4081\/reumatismo.2021.1418","article-title":"A systematic literature review of existing tools used to assess medication adherence in connective tissue diseases: the state of the art for the future development of co-designed measurement tools","volume":"73","author":"Pirri","year":"2021","journal-title":"Reumatismo"},{"key":"2026072006501783000_12.3.e006982.14","article-title":"Criteria for diagnosis of Beh\u00e7et\u2019s disease","volume":"335","year":"1990","journal-title":"The Lancet"},{"key":"2026072006501783000_12.3.e006982.15","first-page":"666","article-title":"Adherence to medication during pregnancy in systemic autoimmune diseases: results from a prospective study","volume":"42","author":"Zucchi","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"2026072006501783000_12.3.e006982.16","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1456063","article-title":"Challenges and opportunities in transitional care process in Beh\u00e7et\u2019s syndrome","volume":"11","author":"Di Cianni","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2026072006501783000_12.3.e006982.17","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004989","article-title":"EducAR: implementing a multicomponent strategy to improve therapeutic adherence in rheumatoid arthritis","volume":"11","author":"Ahij\u00f3n Lana","year":"2025","journal-title":"RMD Open"},{"key":"2026072006501783000_12.3.e006982.18","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s00296-017-3763-9","article-title":"A systematic review of the barriers affecting medication adherence in patients with rheumatic diseases","volume":"37","author":"Goh","year":"2017","journal-title":"Rheumatol Int"},{"key":"2026072006501783000_12.3.e006982.19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jbspin.2020.04.017","article-title":"Adherence to hydroxychloroquine in patients with systemic lupus: contrasting results and weak correlation between assessment tools","volume":"87","author":"Hachulla","year":"2020","journal-title":"Joint Bone Spine"},{"key":"2026072006501783000_12.3.e006982.20","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/cpt.885","article-title":"A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires","volume":"103","author":"Costedoat-Chalumeau","year":"2018","journal-title":"Clin Pharmacol Ther"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2026-006982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:50:26Z","timestamp":1784555426000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2026-006982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,20]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/rmdopen-2026-006982"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2026-006982","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}